Sanofi picks up regulatory wins for new MS, diabetes drugs; Eleven gains early clinical success for dry-eye drug;

@FierceBiotech: ICYMI yesterday: J&J's pharma chairman lands 'more deals' in Boston innovation push. News | Follow @FierceBiotech

 @JohnCFierce: Where are the FDA approvals on biosims? EMA backs two Remicade knockoffs. Release | Follow @JohnCFierce

@RyanMFierce: Big week for Prosensa. Priced $78M IPO on the heels of breakthrough status for lead DMD Rx partnered w/ GSK. PR | More | Follow @RyanMFierce

> The Japanese government has stamped an approval on Sanofi's ($SNY) GLP-1 drug for Type 2 diabetes Lyxumia. Report

> Eleven Biotherapeutics revealed upbeat initial data from a Phase Ib/IIa clinical trial of the company's candidate EBI-005 for patients with dry eye disease. Release

> German healthcare products firm Fresenius reported the sale of its biotech business to the group that owns Israel's Neopharm. Item

Pharma News

@FiercePharma: Finally… EMA's press release about this week's drug moves: Release | Follow @FiercePharma

@EricPFierce: There is a connection between the separate deals Aspen has announced with MSD and GSK. It is heparin. More | Follow @EricPFierce

@CarlyHFierce: There are billions of dollars to be saved on healthcare spending via adherence... but how? Story | Follow @CarlyHFierce

> FDA sends J&J CRL on Xarelto for stent thrombosis. Article

> Dendreon's Provenge gets recommendation in Europe. More

> Pfizer returns to buyback strategy to appease shareholders. Report

Medical Device News

@FierceMedDev: Boston Scientific buying Bard's electrophysiology biz for $275M. News | Follow @FierceMedDev

@DamianFierce: For CROs big and small, you're only as good as your reputation. The view from DIA 2013: Feature | Follow @DamianFierce

@MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Story | Follow @MichaelGFierce

> Despite deaths, docs and patients sticking with Medtronic pump. Item

> Roche Diagnostics scores another FDA victory. Story

> Philips inks $300M deal for service and R&D. News

> Industry: Tightening EU device regs will strangle business. Article

And Finally… Sanofi's Genzyme prevailed in gaining nods from EMA experts that support approval of two MS drugs from the company, Lemtrada and Aubagio. Report

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.